TY  - CONF

T1  - A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy (HT) ± radium-223 dichloride (Ra-223) in HER2<sup>-</sup> hormone receptor<sup>+</sup> breast cancer patients (pts) with bone metastases (mets).

JO  - Journal of Clinical Oncology

UR  - http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps1104

PY  - 2015/05/20

AU  - Coleman RE

AU  - Huang L

AU  - Petrenciuc O

AU  - Zaccarini P

ED  - 

DO  - DOI: 10.1200/jco.2015.33.15_suppl.tps1104

PB  - American Society of Clinical Oncology (ASCO)

VL  - 33

IS  - 15_suppl

SP  - TPS1104

EP  - TPS1104

Y2  - 2025/10/10

ER  -